Hormone Molecular Biology and Clinical Investigation · 2021 · 12 citations · 25 references
MedicineOncologyPharmacologyCell SignalingSignal TransductionTumor ProgressionCancer Cell SignalingCancer ProgressionLiver CancerLiver DiseaseMetastatic Signaling PathwaysOncogenic Signaling PathwaysErk SignalingExtracellular Signal-regulated Kinase PathwayNicotinamide PhosphoribosyltransferasePhosphatidylinositol 3-Kinase-akt PathwayPhosphatidylinositol 3-Kinase-akt SignalingPi3 Kinase-akt SignalingPi3k InhibitorsPi3k-akt Signaling Pathway
OBJECTIVES: Visfatin is found in adipose tissue and is referred to as nicotinamide phosphoribosyltransferase (Nampt). Visfatin has anti-apoptotic, proliferative, and metastatic properties and may mediate its effects via ERK and PI3K/Akt signaling. Studies have yet to determine whether inhibition of kinase signaling will suppress visfatin-induced liver cancer. The purpose of this study was to determine which signaling pathways visfatin may promote liver cancer progression. METHODS: HepG2 and SNU-449 liver cancer cells were exposed to visfatin with or without ERK or PI3K/Akt inhibitor, or both inhibitors combined. These processes that were assessed: proliferation, reactive oxygen species (ROS), lipogenesis, invasion, and matrix metalloproteinase (MMP). RESULTS: Inhibition of PI3K/Akt and combination of inhibitors suppressed visfatin-induced viability. ERK inhibition in HepG2 cells decreased visfatin-induced proliferation. ERK inhibitor alone or in combination with PI3K inhibitors effectively suppressed MMP-9 secretion and invasion in liver cancer cells. PI3K and ERK inhibition and PI3K inhibition alone blocked visfatin's ROS production in SNU-449 cells. These results corresponded with a decrease in phosphorylated Akt and ERK, β-catenin, and fatty acid synthase. CONCLUSIONS: Akt and ERK inhibition differentially regulated physiological changes in liver cancer cells. Inhibition of Akt and ERK signaling pathways suppressed visfatin-induced invasion, viability, MMP-9 activation, and ROS production.
25
Raghu Adya, Bee K. Tan, Anu Punn et al. · Cardiovascular Research · 2007 · 436 citations · Full text
Correlation between Serum Resistin Level and Adiposity in Obese Individuals
Koichiro Azuma, Fuminori Katsukawa, Shuji Oguchi et al. · Obesity Research · 2003 · 369 citations
Patricia Legoix, Olivier Bluteau, Jan Bayer et al. · Oncogene · 1999 · 158 citations